ArticleBMJ neurology open2025
Burden of Duchenne muscular dystrophy in Australia: a scoping review.
Article in BMJ neurology open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Duchenne muscular dystrophy (DMD) is a rare X-linked recessive disorder characterised by progressive muscle degeneration leading to severe disability and early mortality, with no cure. This disease process affects nearly every aspect of daily functioning, from basic movements to respiratory and cardiac functions, and consequently imposes a significant burden on patients, caregivers and families. We aimed to review the available literature examining the epidemiological, health-related quality of life (HRQoL) and economic burden of DMD in Australia from a societal perspective. Methods: This scoping review was conducted by searching Embase and PubMed databases up until 22 August 2024. Two independent reviewers screened titles, abstracts and full texts. Studies that evaluated the epidemiological, HRQoL-related or economic burden of DMD in an Australian-specific context were included. Results: We identified 169 articles and assessed the full text of 32, of which nine were included in the review. Eight studies were observational with one theoretical/computational study. Four studies addressed the epidemiological burden, estimating a birth prevalence of 18.6 to 22.7 DMD cases per 100 000 male live births. Another four studies examined the HRQoL-related burden with three generic patient-reported outcome measures (PROMs) used to assess HRQoL. Two PROMs indicated lower self-reported and parent proxy HRQoL scores in boys with DMD compared with the general population, and the other PROM evaluated parental/caregiver HRQoL. One study detailed the economic burden in 104 households, reporting significant annual socioeconomic burden of DMD associated with high levels of healthcare costs, non-medical resource use and caregiving burden to households. Conclusions: Although the data estimating the epidemiological, HRQoL-related and economic burden of DMD in Australia is limited, existing evidence demonstrates a considerable societal burden of DMD. In the context of emerging disease-modifying therapies for DMD, it provides a summary of existing local evidence and research gaps, highlighting a need for further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.